Table 3.
Predictors of progression-free survival
| Variables | HR | 95 % CI | P |
|---|---|---|---|
| Univariate analysis | |||
| Age | 1.046 | 1.004–1.089 | 0.031 |
| Type of platinum compound used as the first-line (cisplatin vs carboplatin) | 1.670 | 0.750–3.718 | 0.209 |
| TTP of the first-line GP chemotherapy | 0.951 | 0.885–1.022 | 0.175 |
| Cycles of the first-line GP chemotherapy | 0.947 | 0.834–1.076 | 0.404 |
| TFI between GP and MVAC | 0.991 | 0.943–1.042 | 0.735 |
| Primary tumor site | |||
| Bladder vs ureter or renal pelvis/ ureter or renal pelvis with bladder | 1.525 | 0.782–2.975 | 0.216 |
| Bladder/ ureter or renal pelvis vs ureter or renal pelvis with bladder | 1.735 | 0.806–3.733 | 0.159 |
| Nodal status | |||
| N (0 vs 1,2,3) | 1.074 | 0.413–2.789 | 1.074 |
| N (0,1 vs 2,3) | 0.712 | 0.354–1.431 | 0.340 |
| N (0,1,2 vs 3) | 0.541 | 0.246–1.193 | 0.128 |
| Metastatic site | |||
| M0 vs M1 | 1.335 | 0.670–2.658 | 0.411 |
| Lung | 1.502 | 0.798–2.872 | 0.207 |
| Bone | 1.207 | 0.631–2.310 | 0.569 |
| Liver | 1.854 | 0.862–3.987 | 0.114 |
| Others | 1.056 | 0.371–3.007 | 0.919 |
| Multi-organ metastasis (absence vs presence) | 1.696 | 0.874–3.294 | 0.118 |
| Hemoglobin | 0.846 | 0.661–1.082 | 0.182 |
| Absolute neutrophil count | 1.000 | 1.000–1.000 | 0.823 |
| Platelet count | 1.001 | 0.997–1.004 | 1.001 |
| eGFR | 1.000 | 0.979–1.021 | 0.989 |
| Serum bilirubin | 0.529 | 0.077–3.630 | 0.517 |
| Serum albumin | 0.417 | 0.161–1.078 | 0.071 |
| ECOG performance status (0 vs 1,2) | 1.333 | 0.699–2.543 | 0.382 |
| Response to first-line GP | 2.520 | 1.245–5.015 | 0.010 |
| Multivariate | |||
| Age | 1.047 | 1.004–1.093 | 0.033 |
| Response to first-line GP | 2.500 | 1.228–5.098 | 0.012 |
HR hazard ratio, CI confidence interval, TTP time to progression, GP gemcitabine platinum, TFI treatment free interval, MVAC methotrexate vinblastine Adriamycin cisplatin, eGFR estimated glomerular filtration rate, ECOG Easton Cooperative Oncologic Group, Boldface significant 2-tailed